Literature DB >> 24179617

Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome.

Eirini I Rigopoulou1, Kalliopi Zachou, Nikolaos K Gatselis, Georgia Papadamou, George K Koukoulis, George N Dalekos.   

Abstract

AIM: To present the characteristics, management and outcome of patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) infections concurrent with primary biliary cirrhosis (PBC).
METHODS: Since January 2001 to September 2009, we retrospectively evaluated the medical records of all HBV (n = 1493) and HCV patients (n = 526) who are followed in our center for the presence of concurrent PBC. Seventeen patients identified with concurrent viral hepatitis and PBC (8 HCV and PBC; follow-up: 61 ± 37 mo and 9 HBV and PBC; follow-up: 57 ± 38 mo). PBC diagnosis was established if the patients met at least two of the following criteria: positivity for antimitochondrial antibody, elevated cholestatic enzymes and histological lesions of PBC.
RESULTS: HCV or HBV diagnosis preceded that of PBC in most patients by many years. PBC diagnosis was based on the presence of antimitochondrial antibody and elevated cholestatic enzymes in all 17 patients, while one third (5/17; 29.4%) experienced severe pruritus many years before diagnosis. Patients with PBC and HBV were significantly younger at diagnosis of PBC compared to patients with PBC and HCV (56.1 ± 11.2 vs 68.5 ± 10.3, respectively, P < 0.05). At initial clinical and histological assessment the majority of patients were cirrhotics (10/17; 58.8%) with the group of PBC and HCV carrying the highest frequency (87.5% vs 33.3% in PBC and HBV; P < 0.05). The patients with HBV and concomitant PBC seem to have better outcome compared to those with HCV and PBC since none of the 6 non-cirrhotics with HBV and PBC developed cirrhosis during follow-up.
CONCLUSION: PBC diagnosis in HBV or HCV patients is very difficult and usually delayed. Therefore, in any case, cholestasis should alert physicians to further search for PBC.

Entities:  

Keywords:  Antimitochindrial antibodies; Autoimmune liver disease; Hepatitis B virus; Hepatitis C virus; Primary biliary cirrhosis.

Year:  2013        PMID: 24179617      PMCID: PMC3812460          DOI: 10.4254/wjh.v5.i10.577

Source DB:  PubMed          Journal:  World J Hepatol


  34 in total

1.  Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis.

Authors:  E I Rigopoulou; E T Davies; A Pares; K Zachou; C Liaskos; D-P Bogdanos; J Rodes; G N Dalekos; D Vergani
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

2.  Risk factors associated with HCV infection in semi-rural areas of central Greece.

Authors:  Nikolaos K Gatselis; Eirini Rigopoulou; Aggelos Stefos; Maria Kardasi; Georgios N Dalekos
Journal:  Eur J Intern Med       Date:  2007-01       Impact factor: 4.487

3.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Authors: 
Journal:  J Hepatol       Date:  2011-03-01       Impact factor: 25.083

Review 4.  Review article: autoimmune hepatitis -- current management and challenges.

Authors:  K Zachou; P Muratori; G K Koukoulis; A Granito; N Gatselis; A Fabbri; G N Dalekos; L Muratori
Journal:  Aliment Pharmacol Ther       Date:  2013-09-08       Impact factor: 8.171

5.  Non-viral-related pathologic findings in liver needle biopsy specimens from patients with chronic viral hepatitis.

Authors:  Vidhya Nair; Sandra Elisabeth Fischer; Oyedele Adewale Adeyi
Journal:  Am J Clin Pathol       Date:  2010-01       Impact factor: 2.493

6.  Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece.

Authors:  Georgios N Dalekos; Eirini Makri; Stephanie Loges; Petra Obermayer-Straub; Kalliopi Zachou; Thomas Tsikrikas; Elenore Schmidt; Georgia Papadamou; Michael P Manns
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-01       Impact factor: 2.566

7.  Cytochrome P450 2A6: a new hepatic autoantigen in patients with chronic hepatitis C virus infection.

Authors:  Georgios N Dalekos; Petra Obermayer-Straub; Moritz Bartels; Takashi Maeda; Anne Kayser; Sabine Braun; Stephanie Loges; Eleonore Schmidt; M Eric Gershwin; Michael P Manns
Journal:  J Hepatol       Date:  2003-11       Impact factor: 25.083

Review 8.  HBV and HCV chronic infection: autoimmune manifestations and lymphoproliferation.

Authors:  Anna Linda Zignego; Alessia Piluso; Carlo Giannini
Journal:  Autoimmun Rev       Date:  2008-12       Impact factor: 9.754

9.  Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat.

Authors:  Kalliopi Zachou; Alexandros Sarantopoulos; Nikolaos K Gatselis; Themistoklis Vassiliadis; Stella Gabeta; Aggelos Stefos; Asterios Saitis; Panagiota Boura; George N Dalekos
Journal:  World J Hepatol       Date:  2013-07-27

10.  Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis.

Authors:  Stella Gabeta; Gary L Norman; Christos Liaskos; Panagiotis A Papamichalis; Theodoros Zografos; Athanasios Garagounis; Eirini I Rigopoulou; George N Dalekos
Journal:  J Clin Immunol       Date:  2007-05-21       Impact factor: 8.542

View more
  10 in total

1.  Primary biliary cholangitis triggered by DAAs-induced HCV clearance: a biological proof of concept.

Authors:  Maria Rendina; Nicola Maurizio Castellaneta; Giuseppe Losurdo; Antonino Castellaneta; Annamaria Cazzolla; Claudia Chialà; Francesca D'Errico; Alfredo Di Leo
Journal:  Ther Adv Chronic Dis       Date:  2018-02-12       Impact factor: 5.091

2.  A large-scale investigation into the role of classical HLA loci in multiple types of severe infections, with a focus on overlaps with autoimmune and mental disorders.

Authors:  Ron Nudel; Rosa Lundbye Allesøe; Wesley K Thompson; Thomas Werge; Simon Rasmussen; Michael E Benros
Journal:  J Transl Med       Date:  2021-05-31       Impact factor: 5.531

3.  Subtle presentation of active primary biliary cirrhosis in chronic hepatitis B: a case report.

Authors:  Asad Javaid; Mugilan Poongkunran; Felicia D Allard; Win Kyaw; Htet Htet Maung; Daryl Lau
Journal:  Gastroenterol Rep (Oxf)       Date:  2016-02-17

4.  Cholestasis impairs hepatic lipid storage via AMPK and CREB signaling in hepatitis B virus surface protein transgenic mice.

Authors:  Karuna Irungbam; Martin Roderfeld; Hannah Glimm; Felix Hempel; Franziska Schneider; Laura Hehr; Dieter Glebe; Yuri Churin; Gertrud Morlock; Imanuel Yüce; Elke Roeb
Journal:  Lab Invest       Date:  2020-07-01       Impact factor: 5.662

5.  Promyelocytic Leukemia Antigen Expression: a Histological Marker for Primary Biliary Cholangitis Diagnosis?

Authors:  Panagiotis A Papamichalis; Kalliopi Zachou; Roidoula A Papamichali; Maria Ioannou; Nikolaos K Gatselis; George N Dalekos; George K Koukoulis
Journal:  J Transl Int Med       Date:  2021-03-31

Review 6.  Recent advances in the diagnosis and treatment of primary biliary cholangitis.

Authors:  Ying-Qiu Huang
Journal:  World J Hepatol       Date:  2016-11-28

7.  Hepatitis B virus surface proteins accelerate cholestatic injury and tumor progression in Abcb4-knockout mice.

Authors:  Daniel Zahner; Hannah Glimm; Tomomitsu Matono; Yuri Churin; Diran Herebian; Ertan Mayatepek; Kernt Köhler; Stefan Gattenlöhner; Anne Stinn; Annette Tschuschner; Martin Roderfeld; Elke Roeb
Journal:  Oncotarget       Date:  2017-02-02

8.  Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis.

Authors:  Tatsuo Kanda; Shin Yasui; Masato Nakamura; Shingo Nakamoto; Koji Takahashi; Shuang Wu; Reina Sasaki; Yuki Haga; Sadahisa Ogasawara; Tomoko Saito; Kazufumi Kobayashi; Soichiro Kiyono; Yoshihiko Ooka; Eiichiro Suzuki; Tetsuhiro Chiba; Hitoshi Maruyama; Fumio Imazeki; Mitsuhiko Moriyama; Naoya Kato
Journal:  Oncotarget       Date:  2018-02-03

Review 9.  Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma.

Authors:  Yu-Chan Chang; Ming-Huang Chen; Chun-Nan Yeh; Michael Hsiao
Journal:  Biomolecules       Date:  2020-09-28

Review 10.  Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases.

Authors:  Eirini I Rigopoulou; George N Dalekos
Journal:  Cancers (Basel)       Date:  2021-03-01       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.